Abbott stock weekly forecast: Downside risk emerges as volatility stays elevated and recovery remains unconfirmed

Traders Union
All News
Stocks
Abbott Laboratories up 0.02% this week

Highlights

Shares of Abbott closed at $101.98, unchanged for the week and trading below major moving averages.
Technical indicators show oversold conditions with continued bearish structure and weak trend momentum.
For the next five days, expected range is $99.64 to $106.56 with 67% probability of a further decrease.

Legal settlement boosts sentiment as dividend returns reinforce resilience

On September 14, 2026, Abbott Laboratories agreed to pay approximately USD 385 million to settle U.S. infant formula allegations, removing a significant legal overhang for the company. According to www.ad-hoc-news.de and Investing.com, shares initially reacted positively following the announcement. The settlement comes as ABT maintains a robust dividend history, returning $2.1 billion to shareholders in the previous quarter through dividends and buybacks, as highlighted by 24/7 Wall St.

Bearish structure endures as technicals caution against premature reversal

On the daily chart, the structure remains bearish, with price pinned to support at $101.53 and volatility over the past week at 5.15%. Both the CCI at -142.2 and the Stochastic RSI at 7.96 are in oversold zones, signaling stretched downside conditions, while the ADX at 22.64 points to bearish momentum but not a strong developing trend. Resistance is set at $105.45 and the Ichimoku Kijun at $109.41 acts as a secondary barrier. The momentum character is described as an emerging move higher that is not yet confirmed, reflecting uncertainty about a near-term reversal.

Downside risk dominates outlook as support and resistance confine moves

For the next five trading days, the expected range is $99.64 to $106.56, with a 33% probability of an increase and a 67% probability of a decrease. The base case sees Abbott shares fluctuating between support at $101.53 and resistance at $105.45. A sustained move above $105.45 could prompt a recovery toward the upper end of the range, while a clear drop below $101.53 would expose downside risk toward $99.64.

Viktoras Karapetjanc, Traders Union expert, sees the recent $385 million settlement as a significant step forward for Abbott Laboratories, removing a major legal overhang that has weighed on sentiment. He notes that despite current pressure, the technical setup shows shares pinned to support at $101.53 with both the CCI and Stochastic RSI deep in oversold territory, which often precedes opportunity for a rebound. The company’s strong dividend history and active buybacks highlight resilience, even as bearish momentum lingers in the background. Karapetjanc believes a sustained move above $105.45 could trigger renewed demand, opening the path toward the upper end of the expected $99.64 to $106.56 range in the coming week. "Abbott's combination of legal clarity and robust capital returns creates constructive conditions for buyers — I expect further growth as long as support at $101.53 holds."

Earlier, analysts noted that Abbott Laboratories was under persistent selling pressure, with technical signals pointing to continued short- and long-term weakness despite stable institutional support. The recent resolution of major legal overhang adds a new dimension, positioning $101.53 as a pivotal support level to watch in the days ahead as the stock navigates a high-volatility environment.

Source of Data: ABT Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.